- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00424788
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
September 3, 2009 updated by: Biogen
Natalizumab (TYSABRI) is a protein-based drug that is manufactured by Biogen Idec in partnership with Elan Pharmaceuticals.
Natalizumab is approved in the US and Europe for the treatment of Multiple Sclerosis (MS).
The purpose of this study is to determine whether the amount of natalizumab (TYSABRI) that is present in your blood (plasma) can be reduced or eliminated by separating and removing the plasma and replacing it with other fluids, a process called plasma exchange.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
12
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Mellen Center for MS
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53201-0342
- Center for Neurological Disorders, Aurora Health Care
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- considered by the Investigator to be free of signs and symptoms suggestive of any serious opportunistic infection
- willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including interferon beta and glatiramer acetate) for the duration of the study
- willing and able to comply with the site's plasma exchange protocol which may require hospitalization or daily visits
Exclusion Criteria:
- considered by the Investigator to be immunocompromised
- history of, or available abnormal laboratory results indicative of any major disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent for the duration of the study.
- condition(s) considered to be contraindication(s) for plasma exchange, including but not limited to bleeding diathesis, hypotension, or vascular access limitations
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Michael Panzara, MD MPH, Biogen
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2007
Primary Completion (Actual)
October 1, 2007
Study Completion (Actual)
October 1, 2007
Study Registration Dates
First Submitted
January 18, 2007
First Submitted That Met QC Criteria
January 18, 2007
First Posted (Estimate)
January 22, 2007
Study Record Updates
Last Update Posted (Estimate)
September 4, 2009
Last Update Submitted That Met QC Criteria
September 3, 2009
Last Verified
September 1, 2009
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 101MS001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing Forms of Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedMultiple Sclerosis, Relapsing Forms of Multiple SclerosisSpain, Canada, France, Switzerland, Italy, Portugal, Denmark, Poland, Germany, United Kingdom
-
BiogenRecruitingRelapsing Forms of Multiple SclerosisSpain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania
-
BiogenRecruitingRelapsing Forms of Multiple SclerosisChina, Japan
-
Novartis PharmaceuticalsCompletedRelapsing Forms of Multiple SclerosisGermany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing Forms of Multiple SclerosisAustralia, United States
-
BiogenCompletedRelapsing Forms of Multiple SclerosisUnited States, Italy, Switzerland, Canada, Australia, Germany, Spain, France, Portugal, Netherlands, United Kingdom, Denmark, Austria, Ireland
-
Novartis PharmaceuticalsCompletedRelapsing Forms of Multiple SclerosisUnited States, Canada, Puerto Rico
Clinical Trials on Plasma exchange
-
London Health Sciences CentreWithdrawnPurpura, Thrombotic Thrombocytopenic | Hemolytic Uremic SyndromeCanada
-
London Health Sciences CentreCanadian Institutes of Health Research (CIHR); The Kidney Foundation of CanadaCompletedMultiple Myeloma | Acute Renal FailureCanada
-
Peking University Third HospitalNot yet recruitingPregnancy-related Thrombotic Microangiopathies
-
Heidelberg UniversityTerminated
-
Mayo ClinicTerumo BCTCompletedNeuromyelitis Optica | Neuromyelitis Optica Spectrum Disorder | Recurrent Idiopathic Longitudinally Extensive Transverse MyelitisUnited States
-
Larkin Community HospitalUnknown
-
Forsyth Medical CenterNot yet recruiting
-
Alberta Health Services, CalgaryRecruiting
-
University College, LondonUnknown
-
Novacescu AlexandruUniversity of Medicine and Pharmacy "Victor Babes" TimisoaraCompletedAcute Respiratory Distress Syndrome | COVID-19 Pneumonia | COVID-19 Respiratory Infection | Acute Respiratory FailureRomania